Antagonism of Sorafenib and Regorafenib actions by platelet factors in hepatocellular carcinoma cell lines

BACKGROUND: Platelets are frequently altered in hepatocellular carcinoma (HCC) patients. Platelet lysates (hPL) can enhance HCC cell growth and decrease apoptosis. The aims were to evaluate whether hPL can modulate the actions of Sorafenib or Regorafenib, two clinical HCC multikinase antagonists. ME...

Descripción completa

Detalles Bibliográficos
Autores principales: D’Alessandro, Rosalba, Refolo, Maria G, Lippolis, Catia, Giannuzzi, Grazia, Carella, Nicola, Messa, Caterina, Cavallini, Aldo, Carr, Brian I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4038078/
https://www.ncbi.nlm.nih.gov/pubmed/24885890
http://dx.doi.org/10.1186/1471-2407-14-351

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4038078/
https://www.ncbi.nlm.nih.gov/pubmed/24885890
http://dx.doi.org/10.1186/1471-2407-14-351

Ejemplares similares